Clinical Infections: ECCMID 2023
Complicated Clinical Infections: Clinical Impact of New Data From ECCMID 2023

Released: May 03, 2023

David Van Duin
David Van Duin, MD, PhD, FIDSA, FAST

Activity

Progress
1
Course Completed

In this episode, David van Duin, MD, PhD, FIDSA, FAST, discusses new data on complicated clinical infections presented at ECCMID 2023, including:

  • Gram-negative resistance
    • Pharmacokinetic and clinical outcomes in patients receiving meropenem/vaborbactam for KPC-producing carbapenem-resistant Enterobacterales infections
    • Comparative study of cefiderocol- vs colistin-containing regimens for CRAB VAP with concomitant bacteremia
    • Real-world use of imipenem/cilastatin/relebactam for the treatment of infections caused by multidrug-resistant organisms
  • Antimicrobial stewardship
    • Safety and efficacy of antibiotic de-escalation from an antipseudomonal β-lactam in patients with Enterobacterales BSIs in SIMPLIFY
    • The SOAB study comparing clinical outcomes of switching to oral antibiotics after IV lead-in therapy vs continuing IV therapy in patients with Enterobacterales BSIs
    • Data from REGARD-VAP on outcomes of shortened antibiotic treatment for VAP guided by clinical criteria
  • Investigational agents
    • Open-label study following ATTACK of patients with colistin-resistant CRAB infections receiving sulbactam/durlobactam
    • Summary of findings from EAGLE-2 and EAGLE-3 of gepotidacin for uncomplicated UTI treatment
    • Post hoc DOOR analysis of SURE-2 of sulopenem for the treatment of complicated UTIs